Since 2005, the American Psychiatric Association has recommended BLT as a treatment option for patients with major depressive ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Cybin Inc. CYBN has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead ...

Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...